Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Liabilities from Discontinued Operations (2022 - 2024)

Historic Liabilities from Discontinued Operations for Arcadia Biosciences (RKDA) over the last 3 years, with Q2 2024 value amounting to $240000.0.

  • Arcadia Biosciences' Liabilities from Discontinued Operations changed N/A to $240000.0 in Q2 2024 from the same period last year, while for Jun 2024 it was $240000.0, marking a year-over-year change of. This contributed to the annual value of $500000.0 for FY2023, which is 182307.69% up from last year.
  • Per Arcadia Biosciences' latest filing, its Liabilities from Discontinued Operations stood at $240000.0 for Q2 2024.
  • Arcadia Biosciences' 5-year Liabilities from Discontinued Operations high stood at $500000.0 for Q4 2023, and its period low was $26000.0 during Q4 2022.
  • For the 3-year period, Arcadia Biosciences' Liabilities from Discontinued Operations averaged around $199250.0, with its median value being $135500.0 (2023).
  • Within the past 5 years, the most significant YoY rise in Arcadia Biosciences' Liabilities from Discontinued Operations was 182307.69% (2023), while the steepest drop was 182307.69% (2023).
  • Over the past 3 years, Arcadia Biosciences' Liabilities from Discontinued Operations (Quarter) stood at $26000.0 in 2022, then skyrocketed by 1823.08% to $500000.0 in 2023, then crashed by 52.0% to $240000.0 in 2024.
  • Its last three reported values are $240000.0 in Q2 2024, $500000.0 for Q4 2023, and $31000.0 during Q3 2023.